Dicerna Pharma (DRNA) Tops Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. CVI
10. HNGE

Go back to Dicerna Pharma (DRNA) Tops Q1 EPS by 2c

Dicerna Reports First Quarter 2017 Financial and Operational Results and Provides Corporate Update

May 8, 2017 4:05 PM EDT

Management to Host Conference Call Today at 4:30 p.m. ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2017.

While continuing to focus on our research and development activities during the first quarter, we announced a major $70.0 million convertible preferred stock financing, which subsequently closed on April 11, 2017, said Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna. The financing, led by Bain Capital... More